Related references
Note: Only part of the references are listed.Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics
Dino Luethi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Dino Luethi et al.
NEUROPHARMACOLOGY (2018)
Pharmacological profile of mephedrone analogs and related new psychoactive substances
Dino Luethi et al.
NEUROPHARMACOLOGY (2018)
Pharmacological profile of methylphenidate-based designer drugs
Dino Luethi et al.
NEUROPHARMACOLOGY (2018)
Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats
Joshua S. Elmore et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects
Patrick Vizeli et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms
Rosario Moratalla et al.
PROGRESS IN NEUROBIOLOGY (2017)
Pharmacokinetic, Ambulatory, and Hyperthermic Effects of 3,4-Methylenedioxy-N-Methylcathinone (Methylone) in Rats
Kristyna Stefkova et al.
FRONTIERS IN PSYCHIATRY (2017)
Pharmacological mechanisms underlying the cardiovascular effects of the bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV)
Charles W. Schindler et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters
F. P. Mayer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals
Yasmin Schmid et al.
PHARMACOGENETICS AND GENOMICS (2016)
Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects
Sebastien Anizan et al.
ADDICTION BIOLOGY (2016)
Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters
Walter Sandtner et al.
MOLECULAR PHARMACOLOGY (2016)
Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine
Fabio Del Bello et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Pharmacological profile of novel psychoactive benzofurans
Anna Rickli et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones
Anna Rickli et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry
Kayla N. Ellefsen et al.
FORENSIC TOXICOLOGY (2015)
Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans
Andrea E. Steuer et al.
DRUG METABOLISM AND DISPOSITION (2015)
3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry
Sebastien Anizan et al.
ANALYTICA CHIMICA ACTA (2014)
Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats
Charles W. Schindler et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Nonlinear Pharmacokinetics of (±)3, 4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat
Marta Concheiro et al.
DRUG METABOLISM AND DISPOSITION (2014)
Substituted methcathinones differ in transporter and receptor interactions
Amy J. Eshleman et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Pharmacological characterization of designer cathinones in vitro
L. D. Simmler et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive 'Bath Salts' Products
Michael H. Baumann et al.
NEUROPSYCHOPHARMACOLOGY (2013)
An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as bath salts
Raul Lopez-Arnau et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
In Vitro Metabolism and Pharmacokinetic Studies on Methylone
Anders Just Pedersen et al.
DRUG METABOLISM AND DISPOSITION (2013)
The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue
Michael H. Baumann et al.
NEUROPSYCHOPHARMACOLOGY (2012)
MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
Rafael de la Torre et al.
Frontiers in Genetics (2012)
Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity
E. Escubedo et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Induction of glutathione synthesis and conjugation by 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dihydroxymethamphetamine (HHMA) in human and rat liver cells, including the protective role of some antioxidants
Irene Antolino-Lobo et al.
TOXICOLOGY (2011)
Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS
Markus R. Meyer et al.
JOURNAL OF MASS SPECTROMETRY (2010)
Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry
Sabina Strano-Rossi et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2010)
Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat
Michael H. Baumann et al.
DRUG METABOLISM AND DISPOSITION (2009)
Further Studies on the Role of Metabolites in (±)-3,4-Methylenedioxymethamphetamine-Induced Serotonergic Neurotoxicity
Melanie Mueller et al.
DRUG METABOLISM AND DISPOSITION (2009)
The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers
Markus R. Meyer et al.
DRUG METABOLISM AND DISPOSITION (2008)
Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('ecstasy') cytotoxicity
Helena Carmo et al.
PHARMACOGENETICS AND GENOMICS (2006)
Metabolism of the recently encountered designer drug, methylone, in humans and rats
H. T. Kamata et al.
XENOBIOTICA (2006)
1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors
PC Meltzer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice
I Escobedo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans - Use of paroxetine as a metabolic inhibitor probe
M Segura et al.
CLINICAL PHARMACOKINETICS (2005)
Human pharmacology of MDMA -: Pharmacokinetics, metabolism, and disposition
R de la Torre et al.
THERAPEUTIC DRUG MONITORING (2004)
The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus
ML Forsling et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
3,4-dihydroxymethamphetamine (HHMA).: A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans
M Segura et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2001)
Identification of the human cytochromes P450 involved in the oxidative metabolism of Ecstasy-related designer drugs
KP Kreth et al.
BIOCHEMICAL PHARMACOLOGY (2000)